Depression added to Vytorin, Zetia labels

Apparently, it's not only investors and company execs that are depressed by the cholesterol meds Vytorin and Zetia. The FDA has approved a label change adding depression as a possible side effect of the drugs. The agency said the new language will be added to post-marketing adverse reactions, and it will be listed as a potential side effect in another section of the package insert.

Of course, Vytorin and Zetia have been under pressure since last month's release of a trial showing that Vytorin--a combo of simvastatin and Zetia--didn't slow artery clogging any better than simvastatin alone, despite cutting "bad" cholesterol more effectively. Made by Merck and Schering-Plough, Vytorin has lost market share since the study was released, and both companies' have seen their stock suffer--though their shares have since rebounded somewhat. One analyst has even elevated Schering to a "buy" rating.

- check out the FDA's letter to Merck about the label change
- get the agency's letter to Schering-Plough
- read the Dow Jones story
- see more in the Philadelphia Inquirer
- check out the Schering stock news in the Houston Chronicle

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.